Journal of Neuro-Oncology

, Volume 138, Issue 3, pp 581–589 | Cite as

Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody

  • Masahide MatsudaEmail author
  • Eiichi Ishikawa
  • Tetsuya Yamamoto
  • Kentaro Hatano
  • Akira Joraku
  • Yuichi Iizumi
  • Yosuke Masuda
  • Hiroyuki Nishiyama
  • Akira Matsumura
Clinical Study


Tumor angiogenesis has attracted increasing attention because of its potential as a valuable marker in the differential diagnosis of brain tumors as well as a novel therapeutic target. Prostate-specific membrane antigen (PSMA) is expressed by the neovasculature endothelium of some tumors, with little to no expression by the tumor cells or normal vasculature endothelium. The aim of this study was to investigate the potential of PSMA for the evaluation of the tumor neovasculature of various brain tumors and the possibility of detecting PSMA expression in brain tumors using PET imaging with 89Zr-Df-IAB2M (anti-PSMA minibody). Eighty-three tissue specimens including gliomas, metastatic brain tumors, primary central nervous system lymphomas (PCNSL), or radiation necroses were analyzed by immunohistochemical staining with PSMA antibody. 89Zr-Df-IAB2M PET scans were performed in three patients with recurrent high-grade gliomas or metastatic brain tumor. PSMA was highly expressed in the vascular endothelium of high-grade glioma and metastatic brain tumor, whereas PSMA was poorly expressed in the vascular endothelium of PCNSL and radiation necrosis. PSMA expression in high-grade gliomas and a metastatic brain tumor was clearly visualized by PET imaging with 89Zr-Df-IAB2M. Furthermore, a trend toward a positive correlation between the degree of 89Zr-Df-IAB2M uptake and PSMA expression levels in tumor specimens was observed. PET imaging of PSMA using 89Zr-Df-IAB2M may have potential value in the differential diagnosis of high-grade glioma from PCNSL or radiation necrosis as well as in the prediction of treatment efficacy and assessment of treatment response to bevacizumab therapy for high-grade glioma.


Prostate specific membrane antigen Brain tumor Tumor neovasculature PET 



We wish to thank the members of the Tsukuba Clinical Research & Development Organization (T-CReDO) for their critical advice in conducting the study and data management during the study period. We would like to thank the members of the Tsukuba Molecular Imaging Center for carrying out PET imaging.


Research funding was provided by grants from ImaginAb (Los Angeles, CA, USA) and the University of Tsukuba Hospital. ImaginAb also covered manufacturing and shipment costs of 89Zr-Df-IAB2M.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.


  1. 1.
    Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364CrossRefPubMedGoogle Scholar
  2. 2.
    Fisher MJ, Adamson PC (2002) Anti-angiogenic agents for the treatment of brain tumors. Neuroimaging Clin N Am 12:477–499CrossRefPubMedGoogle Scholar
  3. 3.
    Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN (2008) Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26:271–278. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Matsuda M, Ishikawa E, Yamamoto T, Akutsu H, Takano S, Matsumura A (2017) Efficacy of bevacizumab therapy in recurrent malignant gliomas in relation to the prior recurrence pattern or tumor location. J Clin Neurosci 40:115–119. CrossRefPubMedGoogle Scholar
  5. 5.
    Covarrubias DJ, Rosen BR, Lev MH (2004) Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist 9:528–537. CrossRefPubMedGoogle Scholar
  6. 6.
    Daumas-Duport C (1992) Histological grading of gliomas. Curr Opin Neurol Neurosurg 5:924–931PubMedGoogle Scholar
  7. 7.
    Kiess AP, Banerjee SR, Mease RC, Rowe SP, Rao A, Foss CA, Chen Y, Yang X, Cho SY, Nimmagadda S, Pomper MG (2015) Prostate-specific membrane antigen as a target for cancer imaging and therapy. Quart J Nucl Med Mol Imaging 59:241–268Google Scholar
  8. 8.
    Pandit-Taskar N, O’Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M, Keppler JS, Reiter RE, Wu AM, Weber WA, Scher HI, Larson SM, Morris MJ (2016) First-in-human imaging with 89Zr-Df-IAB2M Anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake. J Nucl Med 57:1858–1864. CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59:3192–3198PubMedGoogle Scholar
  10. 10.
    Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57:3629–3634PubMedGoogle Scholar
  11. 11.
    Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH (2007) Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 25:540–547. CrossRefPubMedGoogle Scholar
  12. 12.
    Nomura N, Pastorino S, Jiang P, Lambert G, Crawford JR, Gymnopoulos M, Piccioni D, Juarez T, Pingle SC, Makale M, Kesari S (2014) Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int 14:26. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wernicke AG, Edgar MA, Lavi E, Liu H, Salerno P, Bander NH, Gutin PH (2011) Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Arch Pathol Lab Med 135:1486–1489. CrossRefPubMedGoogle Scholar
  14. 14.
    Holland JP, Sheh Y, Lewis JS (2009) Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol 36:729–739. CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kawai N, Lin W, Cao WD, Ogawa D, Miyake K, Haba R, Maeda Y, Yamamoto Y, Nishiyama Y, Tamiya T (2014) Correlation between (1)(8)F-fluoromisonidazole PET and expression of HIF-1alpha and VEGF in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol Imaging 41:1870–1878. CrossRefPubMedGoogle Scholar
  16. 16.
    Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, Muigg A, Virgolini IJ, Staffen W, Trinka E, Gotwald T, Jacobs AH, Stockhammer G (2011) O-(2-18F-fluoroethyl)-l-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med 52:856–864. CrossRefPubMedGoogle Scholar
  17. 17.
    Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W (2012) 3′-deoxy-3′-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med 53:29–36. CrossRefPubMedGoogle Scholar
  18. 18.
    Delishaj D, Ursino S, Pasqualetti F, Cristaudo A, Cosottini M, Fabrini MG, Paiar F (2017) Bevacizumab for the treatment of radiation-induced cerebral necrosis: a systematic review of the literature. J Clin Med Res 9:273–280. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Makino K, Hirai T, Nakamura H, Murakami R, Kitajima M, Shigematsu Y, Nakashima R, Shiraishi S, Uetani H, Iwashita K, Akter M, Yamashita Y, Kuratsu J (2011) Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study. Ann Nucl Med 25:432–438. CrossRefPubMedGoogle Scholar
  20. 20.
    Yamasaki F, Takayasu T, Nosaka R, Amatya VJ, Doskaliyev A, Akiyama Y, Tominaga A, Takeshima Y, Sugiyama K, Kurisu K (2015) Magnetic resonance spectroscopy detection of high lipid levels in intraaxial tumors without central necrosis: a characteristic of malignant lymphoma. J Neurosurg 122:1370–1379. CrossRefPubMedGoogle Scholar
  21. 21.
    Kim YH, Oh SW, Lim YJ, Park CK, Lee SH, Kang KW, Jung HW, Chang KH (2010) Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. Clin Neurol Neurosurg 112:758–765. CrossRefPubMedGoogle Scholar
  22. 22.
    Takenaka S, Asano Y, Shinoda J, Nomura Y, Yonezawa S, Miwa K, Yano H, Iwama T (2014) Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis. Neurol Med Chir 54:280–289CrossRefGoogle Scholar
  23. 23.
    Zhang H, Ma L, Wu C, Xu BN (2015) Performance of SPECT in the differential diagnosis of glioma recurrence from radiation necrosis. J Clin Neurosci 22:229–237. CrossRefPubMedGoogle Scholar
  24. 24.
    Deri MA, Zeglis BM, Francesconi LC, Lewis JS (2013) PET imaging with (8)(9)Zr: from radiochemistry to the clinic. Nucl Med Biol 40:3–14. CrossRefPubMedGoogle Scholar
  25. 25.
    Wu AM (2009) Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med 50:2–5. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Masahide Matsuda
    • 1
    Email author return OK on get
  • Eiichi Ishikawa
    • 1
  • Tetsuya Yamamoto
    • 1
  • Kentaro Hatano
    • 2
  • Akira Joraku
    • 3
  • Yuichi Iizumi
    • 4
  • Yosuke Masuda
    • 1
  • Hiroyuki Nishiyama
    • 3
  • Akira Matsumura
    • 1
  1. 1.Department of Neurosurgery, Faculty of MedicineUniversity of TsukubaTsukubaJapan
  2. 2.Department of Applied Molecular Imaging, Faculty of MedicineUniversity of TsukubaTsukubaJapan
  3. 3.Department of Urology, Faculty of MedicineUniversity of TsukubaTsukubaJapan
  4. 4.Tsukuba Clinical Research & Development OrganizationUniversity of Tsukuba HospitalTsukubaJapan

Personalised recommendations